WO2019009809A1 - BALLOON CATHETER OF DRUG DELIVERY - Google Patents

BALLOON CATHETER OF DRUG DELIVERY Download PDF

Info

Publication number
WO2019009809A1
WO2019009809A1 PCT/SG2018/050328 SG2018050328W WO2019009809A1 WO 2019009809 A1 WO2019009809 A1 WO 2019009809A1 SG 2018050328 W SG2018050328 W SG 2018050328W WO 2019009809 A1 WO2019009809 A1 WO 2019009809A1
Authority
WO
WIPO (PCT)
Prior art keywords
balloon
sheath
distal end
lumen
drug
Prior art date
Application number
PCT/SG2018/050328
Other languages
English (en)
French (fr)
Inventor
Jingnan LUO
Honglei WANG
Moses Lee
Original Assignee
Vascuros Medical
Vascuros Medical (Shanghai) Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascuros Medical, Vascuros Medical (Shanghai) Co., Ltd. filed Critical Vascuros Medical
Priority to CN201880044739.9A priority Critical patent/CN111491687B/zh
Publication of WO2019009809A1 publication Critical patent/WO2019009809A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/104—Balloon catheters used for angioplasty
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • A61M25/0069—Tip not integral with tube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0097—Catheters; Hollow probes characterised by the hub
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/0105—Steering means as part of the catheter or advancing means; Markers for positioning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/09—Guide wires
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
    • A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
    • A61M25/0026—Multi-lumen catheters with stationary elements
    • A61M2025/0039—Multi-lumen catheters with stationary elements characterized by lumina being arranged coaxially
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
    • A61M2025/0046—Coatings for improving slidability
    • A61M2025/0047—Coatings for improving slidability the inner layer having a higher lubricity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M2025/0062—Catheters; Hollow probes characterised by structural features having features to improve the sliding of one part within another by using lubricants or surfaces with low friction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M2025/0183—Rapid exchange or monorail catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M2025/0186—Catheters with fixed wires, i.e. so called "non-over-the-wire catheters"
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/09—Guide wires
    • A61M2025/09166—Guide wires having radio-opaque features
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1063—Balloon catheters with special features or adapted for special applications having only one lumen used for guide wire and inflation, e.g. to minimise the diameter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1081—Balloon catheters with special features or adapted for special applications having sheaths or the like for covering the balloon but not forming a permanent part of the balloon, e.g. retractable, dissolvable or tearable sheaths
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M25/005—Catheters; Hollow probes characterised by structural features with embedded materials for reinforcement, e.g. wires, coils, braids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/0105—Steering means as part of the catheter or advancing means; Markers for positioning
    • A61M25/0108—Steering means as part of the catheter or advancing means; Markers for positioning using radio-opaque or ultrasound markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/0172—Exchanging a guidewire while keeping the catheter in place

Definitions

  • the current invention relates to various drug eluting balloons that may be inserted into a lumen in the body of a subject to deposit a drug composition at a desired site of action.
  • Coronary/Peripheral Artery Disease is a common circulatory problem in which plaque builds up in the arteries and limits blood flow to parts of the body.
  • a typical treatment for this condition includes artery bypass surgery, stent placement or balloon angioplasty.
  • stent placement and balloon angioplasty some patients develop a new narrowing of the vessel wall at the site of intervention after a few months, which narrowing is known as restenosis.
  • a drug eluting stent is designed to release one or more drugs for a sufficiently long period of time to inhibit cell hyper-proliferation (and hence stenosis/restenosis).
  • a device capable of providing immediate delivery of a therapeutic composition to the site of treatment, with the device being removed entirely from the site of action would be preferred over a permanent implant - even if said implant were able to be resorbed over time.
  • DEB drug eluting balloon
  • DCB drug coated balloon
  • a drug eluting balloon is coated with an active agent.
  • the DEB acts by transferring an active agent to the vessel wall when the balloon is inflated and pressed against the vessel wall at the desired site of action.
  • the procedure for using a DEB generally entails:
  • an uncoated balloon catheter is inserted into a body lumen and used for prediction to ensure a clear pathway for delivery of the drug coated balloon catheter, which helps to prevent transit loss from the DEB.
  • the uncoated balloon is then removed;
  • a drug coated balloon catheter is then introduced through a guiding catheter/introducer sheath through the pre-cleared lumen towards the site of action;
  • the drug coated balloon catheter is positioned at the site of action (e.g. a lesion in a blood vessel);
  • the balloon is inflated to a predetermined size to radially compress against an atherosclerotic plaque in the lesion to remodel the vessel wall;
  • DEBs avoid late thrombotic problems whilst also reducing early restenosis, simplifying the procedure and reducing the dual antiplatelet duration.
  • DEBs are an innovative solution with a high potential impact on the treatment of patients.
  • DEBs as a class show promise, there remain a number of problems that need to be solved - both with the DEB itself and the associated procedure. These problems are discussed below.
  • one or more drugs are directly coated onto the external surface of the balloon, which surface is usually exposed to circulating blood (or other bodily fluids) during use.
  • the DEB delivery system can suffer from a significant loss of drug while the drug coated balloon is manipulated towards a stenotic or occlusive lesion - these losses may be exacerbated by the distance that the DEB has to travel to reach the site of action, as well as the different diameters and tortuosity of the lumen(s) in question en route to a lesion.
  • a high percentage of drug is usually lost when the balloon catheter passes through the introducer sheath and/or guide catheter and/or the torturous blood vessel before it even reaches the lesion.
  • the drug loss differs on a case-by-case basis, and is often uncontrollable, leading to unpredictability.
  • This unpredictability results in a different DEB efficacy for each patient, leading to inconsistent clinical treatment outcomes.
  • the ideal coating should be easily, rapidly and fully releasable at the site of action.
  • the traditional balloon materials are PET, pebax and nylon, which are hydrophobic. As both the drug and balloon surface are generally hydrophobic, the interaction (adhesion) between the drug and balloon surface is quite strong.
  • the drug molecules also adhere to each other, such that even drug molecules that are not in contact with the balloon surface exhibit a strong adhesion to the balloon (through their adhesion to other drug molecules (direct or indirect) that are adhered to the balloon surface).
  • This adhesion makes it difficult to rapidly and fully release the drug from the balloon surface, which leads to low drug transfer and uptake.
  • a number of methods have been used to try to weaken the interfacial interaction between the drug molecules themselves as well as drug molecules to the balloon surface to improve drug release and transfer. These methods include: (a) the use of small molecule additives to reduce adhesion; (b) treating the balloon surface to become hydrophilic by using mechanical or chemical methods; or (c) forming drug particles on the balloon surface instead of a drug layer.
  • a fixed wire catheter balloon delivery device comprising:
  • a balloon catheter shaft having an inflation lumen both having a proximal end and a distal end;
  • a wire having a proximal segment and a distal segment
  • a balloon having a proximal end, a distal end and a working portion therebetween, where the proximal end of the balloon is coupled to and in fluid communication with the distal end of the inflation lumen;
  • a sheath having a proximal end and a distal end
  • the sheath is provided in a first position that wholly covers the balloon and is movable relative to the balloon to a second position that exposes at least a portion of the balloon; and part or whole of the distal section of the wire is irreversibly coupled to the distal end of the balloon.
  • the balloon material may be compliant, semi-compliant or non-compliant (e.g. the balloon material may be semi-compliant or non-compliant);
  • the balloon during use or inflation may have a cylindrical or non-cylindrical shape along the whole of its working portion;
  • the therapeutic agent coating may comprise a therapeutic agent selected from one or more of the group consisting of an antiproliferative, immunosuppressive, anti- angiogenic, anti-inflammatory, and anti-thrombotic agent (e.g. the therapeutic agent may be selected from one or more of the group consisting of paclitaxel, rapamycin, everolimus, zotarolimus, umirolimus, tacrolimus, and pimecrolimus (more particularly, the therapeutic agent may be selected from one or more of the group consisting of paclitaxel, rapamycin, zotarolimus and umirolimus (e.g. paclitaxel and rapamycin)));
  • a therapeutic agent selected from one or more of the group consisting of an antiproliferative, immunosuppressive, anti- angiogenic, anti-inflammatory, and anti-thrombotic agent
  • the therapeutic agent may be selected from one or more of the group consisting of paclitaxel, rapamycin, everolimus, z
  • the therapeutic agent coating may further comprise an excipient, selected from one or more of the group consisting of tartaric acid, a sugar, and a sugar alcohol
  • the excipient may be selected from one or more of the group consisting of fructose, glucose, sucrose, lactose, maltose, erythritol, threitol, arabitol, ribitol, mannitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, more particularly, xylitol, tartaric acid, and sorbitol (more particularly the excipient may be selected from one or more of the group consisting of fructose, glucose, sucrose, mannitol, or more particularly, sorbitol, or yet more particularly xylitol, tartaric
  • the balloon catheter shaft may have a tip at the distal end of the shaft, where the tip has a proximal end facing towards the shaft and a distal end facing away from the shaft and the distal end of the outer sheath and the proximal end of the tip proximal may further comprise an interlock mechanism;
  • the distal end of the sheath may be flared relative to the rest of the sheath, such that the distal end has an outer diameter that is larger than the rest of the sheath by from 0.1 % to 75%;
  • the sheath may have an inner lumen and further comprises a suction mechanism in contact with said inner lumen to prevent the formation of air bubbles when the device is used, optionally wherein the suction mechanism may comprises an o-ring bound to the inner lumen at a proximal position relative to the balloon in the first position;
  • the balloon may be partially or fully covered by the therapeutic agent coating layer
  • the distal segment of the wire may have a tip and the tip is in front of the distal end of the balloon.
  • a therapeutic agent as defined in embodiment (c) of the first aspect of the invention in the preparation of a drug delivery device according to the first aspect of the invention (and any technically sensible combination of its embodiments) for the treatment of a disease or condition that causes narrowing or obstruction of a body lumen (e.g. arteries or veins).
  • a drug delivery device for the treatment of a disease or condition that causes narrowing or obstruction of a body lumen (e.g. arteries or veins).
  • a disease or condition that causes narrowing or obstruction of a body lumen e.g. arteries or veins
  • a body lumen e.g. arteries or veins
  • the disease or condition is a vascular condition or a non-vascular condition (e.g. prostatic hyperplasia (BPH), urethral strictures, ureteral strictures, prostate cancer, esophageal strictures, sinus strictures, biliary tract strictures, asthma and chronic obstructive pulmonary disease (COPD)).
  • BPH prostatic hyperplasia
  • urethral strictures urethral strictures
  • ureteral strictures ureteral strictures
  • prostate cancer e.ophageal strictures
  • sinus strictures biliary tract strictures
  • COPD chronic obstructive pulmonary disease
  • an uncoated balloon catheter is introduced for pre-dilation to ensure a clear pathway for delivery of a drug coated balloon catheter;
  • the distal region of the drug coated balloon is positioned at a lesion and the first sheath is retracted in a proximal direction to expose the balloon, or the distal region of the drug coated balloon is positioned before the lesion and the balloon is advanced and positioned at the lesion, thereby exposing the balloon;
  • the balloon is inflated to a predetermined size to radially compress against an atherosclerotic plaque in the lesion to remodel the vessel wall;
  • a rapid exchange drug delivery catheter balloon device comprising:
  • a balloon catheter shaft having an inflation lumen both having a proximal end and a distal end; a balloon having a proximal end, a distal end and a working portion therebetween, where the proximal end of the balloon is coupled to and in fluid communication with the distal end of the inflation lumen;
  • an exit port for a guidewire lumen in the balloon catheter shaft spaced apart in the proximal direction from the proximal end of the balloon;
  • a guidewire lumen where the guidewire lumen runs co-axially through the inflation lumen from a proximal end that extends through the exit port to a distal end that extends through the distal end of the balloon;
  • a sheath having a proximal end and a distal end
  • the sheath is provided in a first position that wholly covers the balloon and is movable relative to the balloon to a second position that exposes at least a portion of the balloon;
  • the sheath further provides a longitudinal opening that accommodates the exit port and enables the relative movement of the sheath with respect to the balloon from the first position to the second position.
  • each second diameter is independently formed by a neck-down portion or an o-ring bound to the inner lumen.
  • the balloon material is compliant, semi-compliant or non-compliant (e.g. the balloon material is semi- compliant or non-compliant); and/or the balloon during use or inflation has a cylindrical or non-cylindrical shape along the whole of its working portion.
  • the therapeutic agent coating comprises a therapeutic agent selected from one or more of the group consisting of an antiproliferative, immunosuppressive, anti-angiogenic, anti-inflammatory, and anti-thrombotic agent.
  • the therapeutic agent is selected from one or more of the group consisting of paclitaxel, rapamycin, everolimus, zotarolimus, umirolimus, tacrolimus, and pimecrolimus.
  • the therapeutic agent is selected from one or more of the group consisting of paclitaxel, rapamycin, zotarolimus and umirolimus (e.g. paclitaxel and rapamycin)).
  • the therapeutic agent coating further comprises an excipient, selected from one or more of the group consisting of tartaric acid, a sugar, and a sugar alcohol.
  • the excipient is selected from one or more of the group consisting of fructose, glucose, sucrose, lactose, maltose, erythritol, threitol, arabitol, ribitol, mannitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, more particularly, xylitol, tartaric acid, and sorbitol.
  • the excipient is selected from one or more of the group consisting of fructose, glucose, sucrose, mannitol, or more particularly, sorbitol, or yet more particularly xylitol, and tartaric acid.
  • the balloon catheter shaft has a tip at the distal end of the shaft, where the tip has a proximal end facing towards the shaft and a distal end facing away from the shaft and the distal end of the outer sheath and the proximal end of the tip proximal further comprise an interlock mechanism.
  • the distal end of the sheath is flared relative to the rest of the sheath, such that the distal end has an outer diameter that is larger than the rest of the sheath by from 0.1 % to 75%.
  • the balloon is partially or fully covered by the therapeutic agent coating layer.
  • the distal segment of the wire has a tip and the tip is in front of the distal end of the balloon.
  • a drug delivery device for the treatment of a disease or condition that causes narrowing or obstruction of a body lumen (e.g. arteries or veins).
  • a body lumen e.g. arteries or veins.
  • a method of treatment or surgery using a drug delivery device to treat a disease or condition that causes narrowing or obstruction of a body lumen (e.g. arteries or veins), optionally wherein the disease or condition is a vascular condition or a non-vascular condition (e.g. prostatic hyperplasia (BPH), urethral strictures, ureteral strictures, prostate cancer, esophageal strictures, sinus strictures, biliary tract strictures, asthma and chronic obstructive pulmonary disease (COPD)).
  • BPH prostatic hyperplasia
  • urethral strictures urethral strictures
  • ureteral strictures ureteral strictures
  • prostate cancer e.ophageal strictures
  • sinus strictures e.g. asthma and chronic obstructive pulmonary disease (COPD)
  • COPD chronic obstructive pulmonary disease
  • an uncoated balloon catheter is introduced for pre-dilation to ensure a clear pathway for delivery of a drug coated balloon catheter;
  • the distal region of the drug coated balloon is positioned at a lesion and the first sheath is retracted in a proximal direction to expose the balloon, or the distal region of the drug coated balloon is positioned before the lesion and the balloon is advanced and positioned at the lesion, thereby exposing the balloon;
  • the balloon is inflated to a predetermined size to radially compress against an atherosclerotic plaque in the lesion to remodel the vessel wall;
  • the balloon is deflated; and (6) the drug coated balloon delivery system is retracted directly, or the first sheath is pushed forward or the balloon is retracted into the first sheath before the drug coated balloon delivery system is retracted.
  • a fixed wire catheter balloon delivery device comprising:
  • a balloon catheter shaft having an inflation lumen both having a proximal end and a distal end;
  • a wire having a proximal segment and a distal segment
  • a balloon having a proximal end, a distal end and a working portion therebetween, where the proximal end of the balloon is coupled to and in fluid communication with the distal end of the inflation lumen;
  • a sheath having a proximal end and a distal end
  • the sheath is provided in a first position that wholly covers the balloon and is movable relative to the balloon to a second position that exposes at least a portion of the balloon; and part or whole of the distal section of the wire is irreversibly coupled to the distal end of the balloon. 22.
  • the balloon material is compliant, semi- compliant or non-compliant (e.g. the balloon material is semi-compliant or non-compliant); and/or
  • the balloon during use or inflation has a cylindrical or non-cylindrical shape along the whole of its working portion.
  • the therapeutic agent coating comprises a therapeutic agent selected from one or more of the group consisting of an antiproliferative, immunosuppressive, anti-angiogenic, anti-inflammatory, and antithrombotic agent.
  • the therapeutic agent is selected from one or more of the group consisting of paclitaxel, rapamycin, everolimus, zotarolimus, umirolimus, tacrolimus, and pimecrolimus.
  • the therapeutic agent is selected from one or more of the group consisting of paclitaxel, rapamycin, zotarolimus and umirolimus (e.g. paclitaxel and rapamycin)).
  • the therapeutic agent coating further comprises an excipient, selected from one or more of the group consisting of tartaric acid, a sugar, and a sugar alcohol.
  • the excipient is selected from one or more of the group consisting of fructose, glucose, sucrose, lactose, maltose, erythritol, threitol, arabitol, ribitol, mannitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, more particularly, xylitol, tartaric acid, and sorbitol.
  • the balloon catheter shaft has a tip at the distal end of the shaft, where the tip has a proximal end facing towards the shaft and a distal end facing away from the shaft and the distal end of the outer sheath and the proximal end of the tip proximal further comprise an interlock mechanism.
  • the sheath has an inner lumen and further comprises a suction mechanism in contact with said inner lumen to prevent the formation of air bubbles when the device is used, optionally wherein the suction mechanism comprises an o-ring bound to the inner lumen at a proximal position relative to the balloon in the first position.
  • each second diameter is independently formed by a neck-down portion or an o-ring bound to the inner lumen.
  • BPH prostatic hyperplasia
  • urethral strictures urethral strictures
  • ureteral strictures ureteral strictures
  • prostate cancer e.ophageal strictures
  • sinus strictures biliary tract strictures
  • COPD chronic obstructive pulmonary disease
  • an uncoated balloon catheter is introduced for pre-dilation to ensure a clear pathway for delivery of a drug coated balloon catheter;
  • the distal region of the drug coated balloon is positioned at a lesion and the first sheath is retracted in a proximal direction to expose the balloon, or the distal region of the drug coated balloon is positioned before the lesion and the balloon is advanced and positioned at the lesion, thereby exposing the balloon;
  • the balloon is inflated to a predetermined size to radially compress against an atherosclerotic plaque in the lesion to remodel the vessel wall;
  • the drug coated balloon delivery system is retracted directly, or the first sheath is pushed forward or the balloon is retracted into the first sheath before the drug coated balloon delivery system is retracted.
  • Fig. 1 (a) depicts a balloon that may be suitable for use in the current invention.
  • Fig. 1 (b) depicts a balloon that may be suitable for use in the current invention further connected to, or integrally formed with, a balloon catheter shaft.
  • Fig. 2 is a conceptual drawing of a drug delivery system.
  • Fig. 3a is a side view of an example of the Initial Design of the drug delivery system of Fig. 2.
  • Fig. 3b is a side view of a slotted hypotube with a longitudinal slot through the hypotube for use in the drug delivery system of Fig. 2.
  • Figure 4 is the design of a conventional rapid exchange balloon shaft.
  • Figure 5 depicts a drug delivery system 1100 according to the current invention.
  • Figure 6a depicts a drug delivery system 200 according to the current invention.
  • Figure 6b depicts a drug delivery system 3100 according to the current invention.
  • Figure 7a depicts the device with the actuation member 145 positioned at the initial position of the device in Fig. 6a.
  • Figure 7b depicts the device with the actuation member 145 positioned at the withdrawn position of the device in Fig. 6a.
  • Figure 8a depicts an example of a device having a distal region with a straight wire tip.
  • Figure 8b depicts an example of a device having a distal region with a bending wire tip.
  • Figure 8c depicts an example of a device having a distal region with a coil wire tip.
  • Figure 9 depicts a delivery system with a tapered wire and inflation lumen.
  • Figure 10a depicts the design of a balloon tip suitable for use in the current invention.
  • Figure 10b depicts a ring structure with longitudinal ridges present at a distal region of an outer sheath suitable for use in the current invention.
  • Figure 10c depicts the cross-sectional design of the balloon tip and distal end of the outer sheath disclosed in Figures 10a and 10b.
  • Figure 1 1a depicts a distal region of the delivery system, of which the outer sheath tip is straight.
  • Figure 1 1 b depicts a distal region of the delivery system, of which the outer sheath tip is flared.
  • Figure 12 depicts a delivery system with a changing outer diameter of outer sheath.
  • Figure 13a depicts a PTCA rapid exchange catheter shaft according to the current invention without an outer sheath.
  • Figure 13b depicts a PTCA drug delivery system 600 according to the current invention, where the balloon is covered by the outer sheath.
  • Figure 13c depicts the outer sheath movement of a PTCA drug delivery system 600 according to the current invention, where the balloon is in a fully exposed position.
  • Figure 13d depicts a PTCA drug delivery system 700 according to the current invention, where the balloon is covered by the outer sheath.
  • Figure 13e depicts a PTCA drug delivery system 700 according to the current invention, where the balloon is pushed forward and exposed.
  • Figures 14a and b depicts a suction mechanism inside the sheath at a position A and a position B, respectively.
  • Figure 15a depicts a PTCA rapid exchange catheter fitted with an O-ring system.
  • Figure 15 b depicts a PTCA rapid exchange catheter fitted with narrowing sections.
  • Fig. 1 (a) depicts a balloon that may be suitable for use in the current invention
  • Fig. 1 (b) depicts said balloon attached to, or integrally formed with, a balloon catheter shaft.
  • the balloon 1 comprises a balloon body 2, which may be made of a suitable material as discussed in more detail hereinbelow, and two balloon shafts 3, 4 at the ends 5, 6 of the balloon.
  • one of the balloon shafts 3 may be connected to a balloon catheter 7, while the other balloon shaft 4 may contain the tip 8 of the balloon catheter.
  • proximal end refers to the end furthest from the tip 8
  • distal end refers to the end closest to said tip
  • the "ends" of a balloon may refer to the portion of a balloon including two tapered portions that are subsequently, respectively, attached to a balloon shaft.
  • the "working portion” of a balloon when used herein, may refer to the non-tapered portion of the balloon between the two tapered ends of the balloon.
  • Fig. 2 is a drug delivery system 10 provides the unifying concept between the devices of the Initial Design and those of the current invention.
  • the drug delivery system of Fig. 2 comprises a balloon 11 with a therapeutic agent 20 coated on its outer surface 12 (not shown in Fig. 2).
  • An outer sheath 30 is positioned outside the balloon 11. The outer sheath 30 can protect the therapeutic agent coated balloon and minimize drug loss during transit of the drug delivery system.
  • Fig. 3a provides a detailed view of the Initial Design, which device is a drug delivery system for percutaneous transluminal angioplasty and percutaneous transluminal coronary angioplasty.
  • the drug delivery system 100 includes a catheter shaft 110 having proximal (close to handle 140) and distal (close to tip 155) end portions.
  • the catheter shaft includes a guidewire lumen 120 and an inflation lumen 130.
  • the guidewire lumen 120 extends to a proximal guidewire port 141 positioned on the side of handle 140.
  • a guidewire can be introduced through the guidewire port 141.
  • a Y-shape junction 173 is formed at the proximal end of the inflation lumen 130 with another branch for guidewire lumen 120.
  • the inflation lumen 130 may be further coupled to a hypotube 160 at the proximal end. Both the hypotube 160 and inflation lumen 130 may be in fluid communication with the inner chamber of the balloon 150.
  • the fluid is introduced into the fluid lumen through a luer adaptor 142 or the like located at the proximal end of the handle 140.
  • the inflation lumen 130 can supply an inflation medium under positive pressure and can withdraw the inflation medium under negative pressure from the balloon 150.
  • the balloon 150 during usage or inflation has a cylindrical shape along its whole working length (i.e.
  • a tip 155 is coupled to the distal end of the balloon
  • the outer deployment sheath 180 may cover the whole catheter shaft except the tip 155.
  • a slotted hypotube 171 may be connected to the proximal end of the outer deployment sheath 180.
  • Fig. 3b shows that a slotted hypotube has a distal end 174 and a proximal end 173.
  • the slotted hypotube further contains a longitudinal slot 177 that runs from a position close to the distal end 174 towards the proximal 173 in a longitudinal direction, as shown in Fig 4.
  • the longitudinal slot 177 allows the relative longitudinal movement of the Y-shape junction along said longitudinal slot 177.
  • the Y-shaped junction may contain a second hypotube (not shown) that runs through the handle up to the Y-shaped junction.
  • the second hypotube may provide a housing within the handle for an inflation lumen 160.
  • the second branch of the Y-shaped junction may contain a guidewire lumen.
  • Fig. 3b also shows that the slotted hypotube structure may further include at least one or more cuts or slits 175 to increase the flexibility of the hypotube towards its distal end.
  • a strain relief device 185 may be located at the distal end of the handle 140.
  • the strain relief has a channel that allows the slotted hypotube 171 to reside within it, so that the slotted hypotube 171 can move relative to the strain relief.
  • the strain relief provides adequate stress distribution during usage of the delivery system and is also intended to avoid undesired bending of the slotted hypotube 171.
  • Fig. 3a shows a triangle clamp shell 172 positioned in the handle 140.
  • the triangle clamp shell 172 has a Y-shape junction, with one branch for guidewire lumen and another branch for the slotted hypotube 171 and the second hypotube, connected to the outer deployment sheath 180 and the inner inflation lumen 130, respectively.
  • the triangle clamp shell 172 may be used to facilitate the relative and independent movement of catheter shaft 110 and outer deployment sheath 180.
  • the handle 140 may also include an actuation member 145 that is configured to shift the longitudinal position of the catheter shaft member relative to the deployment sheath 180.
  • the actuation member 145 can be moved backward by a clinician in order to accomplish proximal retraction of the deployment sheath 180, thereby exposing balloon 150 to the lesion.
  • the actuation member 145 can be moved forward by a clinician in order to move outer sheath forward to cover the deflated balloon 150.
  • the outer deployment sheath can be provided with a generally constant outer and inner diameter.
  • the outer deployment sheath can define a first inner diameter at its proximal end and a second different inner diameter at its distal end. The first diameter can be smaller than the second diameter, and vice versa.
  • the friction force generated between balloon 150 and the outer sheath 180 may be reduced, which can reduce drug loss when the outer sheath 180 moves backward.
  • the inner diameter of the outer sheath may be coated in a second material that acts as a balloon cover. This second material may be selected from a material known to reduce friction, such as PTFE or other lubricious materials mentioned herein.
  • the outer sheath 180 may further include at least one radioopaque marker band 156 on the distal end, as shown in Fig. 3a. This allows the clinician to precisely locate the catheter within the body. It will be appreciated that the use of a radioopaque marker band is generally applicable in all aspects and embodiments of the invention described herein.
  • the design described above is called an design.
  • the balloon catheter of the current invention may also be used in a Rapid Exchange (RX) design.
  • RX Rapid Exchange
  • a conventional OTW design two lumens (guidewire and inflation) run throughout at least the length of the catheter exposed from the handle (in the current invention's OTW designs, only a guidewire with no lumen is used).
  • an RX catheter only the inflation lumen runs throughout the length of the catheter exposed from the handle. This is because the guidewire (and the associated guidewire lumen) is introduced through a rapid exchange exit port positioned somewhere between the handle and the balloon.
  • a conventional RX balloon catheter is shown in Fig, 4.
  • Such conventional RX catheters comprise a catheter shaft defining an inflation lumen 51 having a proximal end and a distal end, a balloon 54 having a proximal end and a distal end, an inner shaft defining a guidewire lumen and a hypotube 52.
  • the distal end of the guidewire lumen is joined to the distal end of the inflatable balloon.
  • the inflation lumen is in fluid communication with the inflatable balloon and the hypotube.
  • the distal end of the inflatable balloon is sealed by the proximal end of the catheter tip S3, and the guidewire shaft 56 is coupled only to the catheter tip S3 and the distal end of the inflatable balloon.
  • a guidewire lumen (that houses a guidewire shaft) is bonded to the inflation lumen to form an exit port 55.
  • the standard balloon catheter contains three basic elements:
  • the balloon catheter profile of a standard balloon catheter with inflation lumen is basically determined by: the inner lumen; the wall thickness of the inner tube; the gap between the inner tube and inflation tube; the wall thickness of the inflation tube; and the balloon folding profile.
  • the balloon catheter profile of the Initial Design is determined by: the inner lumen; the wall thickness of the inner tube; the gap between the inner tube and the inflation tube; the wall thickness of the inflation tube; the balloon folding profile; the gap between the inflation tube/balloon and the outer sheath; and the outer sheath wall thickness.
  • the wall thickness of the movable outer sheath is usually from 0.003" to 0.005", which leads to a profile increase of from 0.006" to 0.010" (excluding the gap between the balloon/inflation tube and the outer sheath). This means that due to the addition of a movable outer sheath, the profile of the Initial Design DCB catheter is bigger than a conventional DCB catheter.
  • a drug coated balloon may be compatible with one of the 5F (for a 4.0 mm balloon diameter), the 6F (for a 5.0-6.0 mm balloon diameters), and the 7F (for a 7 mm balloon diameter) introducer sheaths.
  • a drug coated balloon When a drug coated balloon is fitted with an outer sheath as in the Initial Design drug coated balloon catheter, it may be compatible with 6F (for a 4.0-5.0 mm balloon diameter), and 7F (for a 6.0-7.0 mm balloon diameters) introducer sheaths. It is the similar for other balloon diameters, such as for a balloon having a 2-3.5mm balloon diameter. This makes it challenging to use this Initial Design drug coated balloon catheter for some small, tortuous and complicated arteries, as it will be difficult to deliver such a large-profile balloon catheter to a lesion located in such arteries.
  • the purpose of the inner lumen is to create a channel or passage that can be used to slide the balloon catheter into a vessel over the guidewire, making it easy and convenient to insert the balloon catheter.
  • the size of commercial guidewires are standardised and the most commonly used smallest one is 0.014". Therefore, to be compatible with commercially available guidewires, the diameter of the inner lumen of balloon catheter must complement these standardised guidewire sizes and this means that a balloon catheter of the Initial Design, which includes an outer sheath, will prove challenging to use to reach some lesions in small-diameter arteries.
  • the current invention seeks to solve this problem while maintaining the outer protective sheath. It is believed that the design discussed below can be applied to smaller and complicated lesions, so that a drug can be delivered predictably and in a sufficient amount to the site of the lesion, while causing less trauma to a patient.
  • the present invention overcomes the disadvantages above by:
  • the purpose of (1) and (2) is to reduce the profile of the OTW balloon catheter and simplify surgery.
  • the purpose of (3) is to achieve a consistent and efficient drug delivery to the site of the lesion.
  • the total profile can be reduced 0.008-0.012", which compensates for the increase in profile by inclusion of an outer sheath (i.e. 0.006- 0.008").
  • an outer sheath i.e. 0.006- 0.008"
  • the profile of the entire device is reduced, making it suitable for use in smaller arteries and/or more complex arteries.
  • the term “comprising” is intended to require all components mentioned to be present, but to allow further components to be added. It will be appreciated that the term “comprising” also covers the terms “consisting of” and “consisting essentially of” as subsets, which are limited to only the components mentioned or to only the component mentioned along with some impurities, respectively. For the avoidance of doubt, it is explicitly contemplated that every use of the word “comprising” may be replaced with “consisting of” and “consisting essentially of” and variants thereof.
  • the balloon may be a catheter balloon for a balloon catheter or may be a balloon catheter, for example as depicted in Fig. 1.
  • the balloon may be formed from a compliant, semi-compliant or non-compliant material.
  • compliant as used herein relates to a material that can expand and stretch with increasing pressure to several times its original size during use as a balloon.
  • Complaint balloons may be made from such materials as silicone, latex and thermoplastic elastomer (TPEs) etc.
  • TPEs thermoplastic elastomer
  • the term “semi-compliant” and “non-compliant” as used herein relates to a material for a balloon that can retain its designed size and shape even as the internal balloon pressure increases beyond that required to fully inflate the balloon.
  • the balloons When such materials are used to make a balloon, the balloons may be thin walled and exhibit high tensile strength, with relatively low elongation.
  • Such balloons are made from materials like polyethylene terephthalate (PET), po!yamides (e.g.
  • PE polyethylene
  • PES polyetherimide
  • PES polyetheretherketone
  • PPO polyphenylene oxide
  • PEN poly(ethylene naphthalenedicarboxylate)
  • PEBA polyethylene (for example, arlexTM high-density polyethylene, MarlexTM low-density polyethylene, and a linear low density polyethylene such as REXELLTM), polypropylene (PP), polyetherimide (PEI), po!ytetrafluoroethylene (PTFE), ethylene tetrafiuoroethylene (ETFE), f!uorinated ethylene propylene (FEP), po!yoxymethylene (POM), po!ybutylene terephthalate (PBT), polyvinylchloride (PVC), po!yether-biock-amide (PEBA, for example, available under the trade name PEBAXTM), polyetheretherketone (PEEK), po!yimide (PI), poiyphenylene sulfide (PPS), polypheny
  • the outer sheath 30 (see Fig. 2), is movable relative to the balloon that it covers. As described herein, the outer sheath may be movable in a proximal direction to expose the coating or the balloon may be movable in a distal direction to become unprotected from the outer sheath.
  • the moving distance of the outer sheath relative to balloon catheter may be equal to the length of the balloon or above.
  • the outer sheath can be single layer or multilayer tube.
  • single layer tube are selected from but not limited to polyethylene (PE), Pebax, polyurethane (PU) and Nylon.
  • the multilayer tube may be selected from but not limited to dual layer and tri-layer tube.
  • the inner layer can be attached to or formed with the outer layer.
  • the material for outer jacket may be chosen from PE, Pebax, PU and Nylon.
  • the inner liner may be chosen from polytetrafluoroethylene (PTFE), fluorinated ethylene propylene (FEP), perfluoroalkoxy polymeric material (PFA), PE, Pebax, polyurethane, and Nylon. Lubricious materials which may facilitate the sliding between the inner catheter balloon and the outer sheath are preferred.
  • the preferred material for the inner liner may be selected from but are not limited to PTFE, PFA, FEP or HDPE.
  • a tri-layer tube may include an outer layer, a middle layer and an inner layer.
  • the tri-layer tube may be a braided tube which provides high torque, high pushability, steerability and kink resistance.
  • the middle layer may be a braided wire layer.
  • the materials for the wires may be 304 stainless steel, 316 stainless steel, polyester, nylon and nitinol.
  • the wire density may be 10 to 250 picks per inch, with wire size 0.0005"-0.004" for round wire and 0.0005"x0.003" to 0.002"x0.007" for flat wire.
  • the middle layer can also be formed by using one type of wire or two types of wires.
  • the middle braided layer may be formed by two types of wires, such as yarn and stainless steel.
  • the middle layer can be coil construction.
  • the material for outer jacket may be chosen from but not limited to PE, Pebax, PU and Nylon.
  • the inner liner may be chosen from PTFE, FEP, PFA, PE, Pebax, polyurethane, and Nylon. Lubricious materials which may facilitate the sliding between the inner catheter shaft and the outer deployment sheath is preferred.
  • the preferred material for inner liner may be PTFE, PFA, FEP or HDPE.
  • the outer sheath can have different material at different part of the sheath.
  • the outer sheath can be a braided tube coupled with a dual layer tube.
  • the dual layer tube may have the same outer diameter but larger inner diameter as compared with that of the braided tube.
  • a tri-layer tube may include an outer polymer layer, an inner polymer layer and reinforce layer positioned between outer layer and inner layer.
  • the inner layer provides a low coefficient of friction surface to reduce the forces required to deploy the balloon catheter shaft, which significantly helps to prevent drug coating being scratched off.
  • the inner liner may be chosen from PTFE, FEP, PFA, PE, Pebax, polyurethane, and Nylon. Lubricious material which may facilitate the sliding between the inner catheter shaft and the outer deployment sheath is preferred.
  • the preferred material for inner liner may be PTFE, PFA, FEP or HDPE.
  • Other suitable polymers for inner and outer layer include any suitable material known to those skilled in the art.
  • the middle reinforce layer may be a wire reinforcing layer.
  • the reinforcing layer is preferably made from stainless steel. It may be braided wire or coil wire or both.
  • the proximal region of the reinforcing layer may be made from braided wire and the distal region may be made from coil wire.
  • the configuration of braid layer can be changed to change system performance. This is achieved by changing the pitch of the braid, the shape of the individual braidwires, the number of braidwires, and the braid wire diameter. Additionally, coils could be incorporated into the sheath enhance system flexibility.
  • the material for outer layer may be chosen from but not limited to PE, Pebax, PU and Nylon. The outer sheath can have different material at different part of the sheath.
  • the outer layer can be a series of fused transitions decreasing in material durometer from proximal to distal along outer layer of the sheath.
  • the material in the proximal region may be pebax 72D, while the material in the distal region may be pebax 53D.
  • the inclusion of transitions of varying material durometers can effectively enhance catheter's pushability. This means that the catheter is able to transmit a force applied by the physician at a proximal location on sheath to the distal tip, which aids in navigation across tight stenotic lesions within the vascular anatomy. It also gives the sheath better flexibility at distal region, which makes it easier to reach target artery.
  • the sheath design also gives the sheath better resistance to elongation and necking as a result of tensile loading during sheath retraction.
  • the catheter's performance can be tuned through changing the multilayer structure of the outer sheath.
  • the wall thickness of the outer sheath has to be kept as low as possible, so as to keep the profile of the whole device low.
  • the therapeutic agent coating layer may be selected from one or more of the group consisting of an antiproliferative, immunosuppressive, anti-angiogenic, anti-inflammatory, and anti-thrombotic agent (e.g. the therapeutic agent may be selected from one or more of the group consisting of paclitaxel, rapamycin, everolimus, zotarolimus, umirolimus, tacrolimus, and pimecrolimus (such as a therapeutic agent selected from one or more of the group consisting of paclitaxel, rapamycin, zotarolimus and umirolimus, such as paclitaxel and rapamycin)).
  • an antiproliferative, immunosuppressive, anti-angiogenic, anti-inflammatory, and anti-thrombotic agent e.g. the therapeutic agent may be selected from one or more of the group consisting of paclitaxel, rapamycin, everolimus, zotarolimus, umirolimus, tacrolimus, and pimecrolimus
  • the therapeutic agent may further comprise an excipient, which may be selected from but not limited to one or more of the group consisting of tartaric acid, a sugar, and a sugar alcohol (e.g. the pharmaceutically acceptable carrier may be selected from one or more of the group consisting of fructose, glucose, sucrose, lactose, maltose, erythritol, threitol, arabitol, ribitol, mannitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, more particularly, xylitol, tartaric acid, and sorbitol (such as selected from one or more of the group consisting of fructose, glucose, sucrose, mannitol, or more particularly, sorbitol, or yet more particularly xylitol
  • the therapeutic agent coating layer may further comprise an adhesion balance layer or base coating layer laid directly on the outer hydrophobic surface of the balloon, comprising a hydrophilic polymer and/or a hydrophilic compound.
  • the hydrophilic compound may be selected from one or more of the group consisting of a sugar, a sugar alcohol, and polyethylene glycol (e.g.
  • the hydrophilic compound with a molecular weight of less than 1 ,000 Daltons may be selected from one or more of the group consisting of fructose, glucose, sucrose, lactose, maltose, erythritol, threitol, arabitol, ribitol, mannitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, xylitol, sorbitol and polyethylene glycol (such as selected from one or more of the group consisting of fructose, glucose, sucrose, xylitol, mannitol, and sorbitol)).
  • the adhesion balance layer may be applied using any suitable method, such as, but not limited to, spray coating, immersion or dip-coating and the like.
  • the therapeutic agent coating layer may be applied by mixing together the therapeutic agent and, optionally, an excipient and coating the substrate (e.g. the elastic film or balloon surface) with the mixture, which may include a solvent to enable coating to take place.
  • Methods suitable to achieve the coating include, but are not limited to, spray coating, immersion or dip-coating and the like.
  • the materials used in the catheter shaft, including the inflation lumen and the tip are chosen from any suitable material, which includes, but is not limited to, polymer materials such as nylon, polyurethane, PEEK, PTFE, PVDF, PEBAX, PE.
  • the outer deployment sheath can be constructed of a single layer of a suitable material.
  • suitable materials can include, but are not limited to, polymer materials such as nylon, polyurethane, PEEK, PTFE, PVDF, PEBAX, PE or dual-layer and tri-layer materials selected from the list from nylon, polyurethane, PEEK, PTFE, PVDF, PEBAX, PE. Again, these materials may be generally applicable throughout similar components in other aspects and embodiments of the current invention unless specifically stated.
  • a hypotube or slotted hypotube may be made from a material that comprises a metal or a plastic.
  • Metals that may be used to form the hypotube include, but are not limited to, stainless steel including 302, 304V, 316L or nitinol.
  • Plastics that may be used to form the slotted hypotube include, but are not limited to, polymeric materials such as nylon, polyurethane, PEEK, PTFE, PVDF, PEBAX or PE.
  • a slot may be located in a longitudinal direction at one side of the hypotube, which facilitates the movement of the hypotube coupled to the inner catheter shaft. The width of the slot may be sufficient to enable the movement of the hypotube together with the balloon catheter.
  • the slotted hypotube may further include one or more cuts or slits to improve the flexibility of the hypotube.
  • the pattern in the slotted hypotube may be achieved by laser-cutting or any other suitable method. These features may be generally applicable across all aspects and embodiments of the invention.
  • the slotted hypotube does not need to include a Y-shaped segment, as there is no separate guidewire.
  • a balloon catheter shaft having an inflation lumen both having a proximal end and a distal end; a wire having a proximal segment and a distal segment;
  • a balloon having a proximal end, a distal end and a working portion therebetween, where the proximal end of the balloon is coupled to and in fluid communication with the distal end of the inflation lumen;
  • a sheath having a proximal end and a distal end
  • the sheath is provided in a first position that wholly covers the balloon and is movable relative to the balloon to a second position that exposes at least a portion of the balloon; and part or whole of the distal section of the wire is irreversibly coupled to the distal end of the balloon.
  • a second position that exposes at least a portion of the balloon refers to a position where at least a section of the working portion of the balloon is exposed from the sheath, such that it can inflate and deposit the drug on a lumen.
  • first position and second position are used herein to refer to the intended function of the balloon and are not intended to place any limit on how the balloon is presented for commercial sale. While the balloon may conveniently be fully covered by the sheath in a commercial package for sale, the balloon may also be partly or wholly exposed.
  • the phrase "the sheath is provided in a first position that wholly covers the balloon and is movable relative to the balloon to a second position that exposes at least a portion of the balloon” is intended to cover either the forward movement of the balloon, while keeping the sheath generally stationary or, more particularly, the retraction of the sheath while keeping the balloon generally stationary. In both cases, the sheath moves relative to the balloon.
  • Figures 5 and 6 depict two drug delivery systems according to the current Design, 1100 and 200, respectively, both comprise a balloon catheter shaft, a tip, a wire, an outer sheath and a handle.
  • drug delivery system 1100 includes a catheter shaft 1150, having proximal end (close to handle 1170) and distal (close to tip 1108) end portions.
  • the device also has an outer sheath 1140 that in a first position that wholly encloses a balloon catheter 1150.
  • the balloon catheter shaft 1150 is composed of a balloon 1130 and an inflation tube 1180.
  • the balloon 1130 has a distal leg 1120 and a proximal leg 1122.
  • the inflation tube 1180 is conjugated at the proximal leg 1122 of the balloon 1130 and is in fluid communication with the inner chamber of the balloon 1130.
  • a fluid may be introduced into the fluid lumen through a luer adaptor 1160 or the like located at the proximal end of the handle 1170.
  • the inflation tube 1180 can supply an inflation medium under positive pressure and can withdraw the inflation medium under negative pressure from the balloon 1130.
  • a therapeutic agent 1155 is coated on the outer surface of balloon 1135.
  • the wire 1110 has four segments as shown in Fig. 5(c).
  • the first segment 1102 is embedded in the inflation tube 1180 as shown in cross- section Fig. 5(a).
  • the proximal portion of the first segment is coterminous with the end of the inflation tube 1180.
  • the middle segment 1106 of wire 1110 is located in the balloon 1130 (e.g. the balloon centre as depicted) and penetrate through the distal tip 1125.
  • Segment 1104 is a connector portion between segment 1102 and segment 1106.
  • the distal segment 1108 is conjugated to the distal leg 1120 of the balloon and extends over a tip 1125.
  • the wire 1110 is embedded within the inflation tube 1180 and part of the wire is irreversibly conjugated to the balloon distal leg 1120, the wire is partially in contact with the inflation medium.
  • the distal end of the wire is conjugated with the balloon's distal leg 1120, when the outer sheath 1140 is retracted, there is no relative movement between the wire 1110 and the balloon catheter shaft 1150 during navigation of the device.
  • the balloon catheter described here is a fixed wire balloon catheter.
  • the luer adaptor 1160 of this embodiment is conjugated to both the proximal end of inflation tube 1180 and the proximal end of hypotube 1195.
  • the hypotube 1195 covers the part of the inflation tube 1180 that is located inside the handle.
  • An actuation member 1145, conjugated with the proximal end of the outer sheath 1140, is surrounds part of hypotube 1195.
  • the actuation member 1195 is configured such that the actuation member 1145 can be shifted together with the outer sheath 1140 along the longitudinal direction of the handle as shown in Figure 7.
  • Figure 7a shows the device with the actuation member 1145 positioned at the initial position.
  • the actuation member 1145 When the distal region of the drug delivery system is positioned at a lesion, the actuation member 1145 can be moved backward (relative to the balloon) by a clinician in order to accomplish proximal retraction of the outer sheath 1140, thereby exposing balloon 1130 to the lesion (shown in Figure 7b). After balloon 1130 is deflated and before drug delivery system 1100 is retracted from the body, the actuation member 1145 can be moved forward by a clinician in order to move outer sheath forward to cover the deflated balloon 1130. The clinician can also retract the drug delivery system directly after balloon deflation.
  • system 200 is shown in Figure 6 and is also composed of a balloon catheter shaft 250 comprising a balloon 230 and an inflation tube 280, a tip 225, a wire 210, an outer sheath 240 and a handle 270.
  • the main difference between the balloon catheter of design 1100 and that of design 200 is the wire and inflation tube design.
  • the inflation tube 1180 is a double lumen tube, while in system 200, the inflation tube is a single lumen tube.
  • the wire 210 is in the embodiment of this second design is located at the center of both inflation tube 280 and balloon 230, as shown in cross- section Figure 6.
  • the detailed structure of handle 270 is not shown as it is the same as system 1100 and operates in the same manner as described hereinbefore.
  • the balloon catheter shaft 3150 is composed of a balloon 3130 and an inflation tube 3180.
  • the luer adaptor 3160 of this embodiment is conjugated to only the proximal end the hypotube 3195 (not shown in the drawing).
  • the balloon 3130 has a distal leg 3120 and a proximal leg 3122.
  • the inflation tube 3180 is conjugated at the proximal leg 3122 of the balloon 3130 and is conjugated at the distal end of the hypotube 3195. There will be fluid communication with the inner lumen of the hyptobue 3195, inflation tube 3180 and balloon 3130.
  • the proximal end of wire 3110 is conjugated to the distal of hypotube 3195.
  • the distal end of wire 3110 is conjugated with the balloon distal leg 3120.
  • the wire has a tapered shape at its distal portion.
  • Figures 5 and 6 therefore show different design embodiments of the current invention which differ on how the wire is conjugated to the rest of the DCB system.
  • the wire is composed of a main wire 2215 and a tip 2216 which is located at the distal end of the tip 2215, as shown in Figure 8a.
  • the main wire 2215 is flexible and may, for example, be constructed of a stainless steel material, such as a grade 304 surgical stainless steel.
  • the wire may have a uniform diameter longitudinally or the wire may include segments having tapered configurations of varying diameters.
  • the tapered diameters of these segments may, for example, be selected to provide a desired degree of wire flexibility.
  • the wire may be thicker at the proximal region and may be thinner at the distal region.
  • the diameter may range from 0.005" to 0.035" along the length of the wire.
  • the main wire body may have several tapered segments.
  • the first main body 2201 of the wire embodied in Figure 8a has a diameter D1 and a first tapered segment 2203 that tapers down to a second segment 2205 with diameter D2, and a second tapered segment 2207 that tapers down to a third segment 2209 with diameter D3.
  • the tapered segment 2207 may be located at the distal end of the balloon tip 2225.
  • the third segment 2209 can be the wire core of the wire tip.
  • the wire can only have fewer or more segments with taper regions, which is not shown in the drawings.
  • the tip of the wire can have several configurations as shown in Figure 8. For example, it can have a bending structure (Figure 8b), or straight tip (Figure 8a) or a straight tip with coil (Figure 8c). It also can be a bending coil structure which is not shown in the drawings.
  • the length of the tip may be from 0.5 to 50cm in length, though it is generally preferably from 1 to 20 cm.
  • the portion located at the balloon region may be covered by a polymer jacket with a very thin wall thickness such as from 0.0005 to 0.005".
  • the polymer jacket may have a constant outer diameter (OD) or an OD with tapered profile that follows the OD of the metal wire.
  • the ends of coil can be secured at segment 2207 and at the distal segment 2209 respectively.
  • the coil's OD and ID may follow the shape of the inner segment.
  • the coil is like a spring which is able to resume its helical configuration after being deflected.
  • the change of configuration of the wire distal region will change the stiffness of the wire at that region.
  • the coil design aims to increase the stiffness and improve the trackability of the whole device.
  • a bend may be present as in the wire tip as shown in Figure 8b.
  • the inner bend radius R1 can, for example, be from 0.10 mm to 1.70 mm.
  • the outer bend radius R2 can, for example, be from 0.40 mm 2.10 mm.
  • the bending wire tip feature may be especially suited to traverse a partial or total occlusion of the vessel.
  • the inflation lumen may follow the profile of the wire.
  • the wire 311 has large diameter D4 at proximal segment 312 and a small diameter D5 at distal segment 313, which is inside the inflation tube 380.
  • the inflation tube also has two different segments 381 and 382.
  • the segment 381 also has bigger diameter D6 than that of segment 382, D7.
  • the wire may also include one or more markers constructed of a radiopaque material, such as gold, platinum, iridium or a combination thereof, such as a platinum-iridium alloy, which can be easily viewed on x-rays.
  • a radiopaque material such as gold, platinum, iridium or a combination thereof, such as a platinum-iridium alloy, which can be easily viewed on x-rays.
  • the polymer cover jacket may be made from polyamide or heat shrinkage FEP tube, PET tube etc. Marker bands may be swaged over the polymer cover jacket. The rest of the portion of wire can be covered or uncovered; (2) the marker band may be coated directly on the surface of the wire. The inclusion of markers facilitates monitoring the progression of the whole device in a blood vessel; and
  • the marker band may be swagged directly on the wire.
  • Example locations for markers are illustrated generally at 2217 and 2218 in FIG. 8a.
  • the balloon tip shown in Figure 10a can be made from polyethelyene, Pebax, polyurethane, and Nylon.
  • the distal tip has a tapered shape.
  • the balloon tip is used to:
  • the tip is conjugated with the balloon catheter and the wire, once the proximal portion of the outer sheath is turned during navigation, the whole device can be turned together, including the wire tip. It is very important that the torque can be transferred to the wire tip so the delivery system can be transferred through torturous blood vessels reach the lesion.
  • the outer sheath is movable relative to the balloon. As described herein, the outer sheath may be movable in a proximal direction to expose the coating or the balloon may be movable in a distal direction to become unprotected from the outer sheath.
  • the moving distance of the outer sheath relative to balloon catheter may be less than, or equal to the length of the balloon or above. In other words, the balloon can be inflated when it is fully exposed, or when it is only partially exposed.
  • the outer sheath can be provided with a generally constant outer and inner diameter.
  • the outer deployment sheath can define a first inner diameter at its proximal end and a second different inner diameter at its distal end. The first diameter can be smaller than the second diameter, and vice versa.
  • the friction force generated between balloon and the outer sheath may be reduced, which can reduce drug loss when the outer sheath moves backward.
  • the inner diameter of the outer sheath may be coated in a second material that acts as a balloon cover. This second material may be selected from a material known to reduce friction, such as PTFE or other lubricious materials mentioned herein.
  • the outer deployment sheath may have two different diameters. Additionally, it may be flared at the distal region. This is important if the device's distal region is to be located in a torturous blood vessel. The outer sheath always has some stiffness.
  • the flare percentage of OD may be between 0.1 % to 75%.
  • materials and layers of outer sheaths that may be used herein (e.g. multilayer sheaths, such as dual layer and trilayer sheaths) is provided hereinbefore.
  • the mechanical properties of the device are not only affected by the materials used in the construction of the outer sheath, but are also affected by the dimension and the design of the outer sheath.
  • the wall thickness of the outer sheath may affect the pushability and the torque of the whole system.
  • the wall thickness will affect the profile of the whole device.
  • the outer sheath 440 can have two segments 441 and 442 with different outer diameters. Segment 441 with bigger diameter at the proximal end will improve the pushability of the delivery system, while segment 442 with a smaller diameter at the distal end can keep the profile low, which allows the delivery system to have a low distal profile and reach the occlusion and lesion.
  • a rapid exchange drug delivery catheter balloon device comprising:
  • a balloon catheter shaft having an inflation lumen both having a proximal end and a distal end;
  • a balloon having a proximal end, a distal end and a working portion therebetween, where the proximal end of the balloon is coupled to and in fluid communication with the distal end of the inflation lumen;
  • an exit port for a guidewire lumen in the balloon catheter shaft spaced apart in the proximal direction from the proximal end of the balloon; a guidewire lumen, where the guidewire lumen runs co-axially through the inflation lumen from a proximal end that extends through the exit port to a distal end that extends through the distal end of the balloon;
  • a sheath having a proximal end and a distal end
  • the sheath is provided in a first position that wholly covers the balloon and is movable relative to the balloon to a second position that exposes at least a portion of the balloon;
  • the sheath further provides a longitudinal opening that accommodates the exit port and enables the relative movement of the sheath with respect to the balloon from the first position to the second position.
  • guidewire lumen is as conventionally defined and provides a lumen for the insertion and removal of a guidewire for use in positioning the catheter balloon system at a desired site of action.
  • the RX balloons disclosed herein may be conventionally sized, as described above.
  • exit port refers to an opening in the inflation lumen that admits the guidewire lumen into the interior of the inflation lumen.
  • the opening in the inflation lumen is sealed by at least the wall of the guidewire lumen by any suitable means, such as bonding. Such arrangements are disclosed in the inserts in Figures 13b and 13c.
  • the inflation lumen opening may have extension tube that is then bonded together with guidewire lumen's wall to form a fluid-tight seal.
  • Fig. 13a and Fig. 13c depict a balloon catheter according to this embodiment, where the balloon has been fully exposed, while Fig. 13b, depicts the same embodiment, but with the balloon covered by a sheath as described hereinabove.
  • Fig. 13a depicts a balloon catheter shaft 610 without the outer sheath, the shaft having a proximal end portion and a distal end portion.
  • the shaft of Fig. 13a also includes an inflation lumen 650, a hypotube connection portion or an extension of inflation lumen 623 (which is optional), a guidewire lumen 620, a guide wire 622 (not shown) a balloon 660 and a hypotube 670.
  • the inflation lumen 650 is proximally bonded with hypotube 670 via the hypotube connection portion 623.
  • the hypotube 670 surrounds the hypotube connection portion 623 at its proximal end and the inflation lumen surrounds its distal end, such that only the inflation lumen 650, the hypotube connection portion 623 and the hypotube 670 are in fluid communication with the inner chamber of the expandable balloon 660.
  • the hypotube connection portion 623 is entirely optional and may be omitted from the catheter shaft, in which case the hypotube 670 surrounds the inflation lumen 650 at the proximal end thereof, such that only the inflation lumen 650 and the hypotube 670 are in fluid communication with the inner chamber of the expandable balloon 660.
  • the guidewire lumen 620 extends from the distal end of the balloon 660 to and extends out through an exit port 621 , which is depicted as being located in the inflation lumen 650, but it may equally be located in the hypotube connection portion 623 or the hypotube 670.
  • the exit port 621 is formed by bonding the hypotube connection portion 623, inflation lumen 650 and guidewire lumen 620 together.
  • this arrangement means that the inflation lumen 650 surrounds the guidewire lumen 620 that is internally positioned in the catheter shaft 610.
  • Fig. 13b and Fig. 13c depict a fully-functional delivery system, which in addition to the balloon shaft 610 further includes a handle 630 and an outer sheath 680.
  • the outer sheath 680 has a proximal end attached to an actuation member portion 645 of handle 630 and a distal end that covers the balloon 660 (the outer sheath also covers the inflation lumen and hypotube extending out from the handle).
  • the actuation member 645 is configured to shift the longitudinal position of the catheter shaft member relative to the deployment (or outer) sheath 680.
  • the outer sheath 680 has a longitudinal slot (or opening) 681 that also has a proximal end and a distal end.
  • the exit port abuts or is adjacent to the proximal end of the long slot 681.
  • the actuation member 645 retracts the outer sheath (such that a portion of the outer sheath is retained in the handle), resulting in the movement of the long slot 681 back towards the handle until the exit port 621 abuts the distal end of the long slot, thereby arresting further retraction.
  • the effect of this arrangement is that the guidewire essentially maintains its absolute position while the outer sheath is retracted.
  • the long slot may have any suitable size that enables at least the desired portion of the balloon 660 to be uncovered.
  • the long slot may be sized so at to allow for the balloon to be fully exposed, while in others it may be sized to only allow a portion of the balloon to be exposed if that is a desired outcome.
  • the outer sheath is retracted, while the balloon and guidewire maintain their original positions. It will be appreciated that it is also possible to maintain the original position of the outer sheath, while extending both the guidewire and balloon using actuation member attached to the catheter shaft.
  • Delivery system 700 in Figure 13d and 13e has similar outer and inner shaft design. The difference is that the actuation member 745 is joined to hypotube 735. With guidewire 722 in place, the actuation member 745 can be pushed forward to shift the balloon forward. The guidewire exit from the guidewire lumen extension tube 721 can move forward longitudinally along the slot 781 on the outer sheath 780.
  • Fluid can be introduced into the fluid lumen through a luer adaptor 640 or the like located at the proximal end of the handle 630 (see Fig. 13b and Fig. 13c).
  • the inflation lumen 650 can supply an inflation medium under positive pressure and can withdraw the inflation medium under negative pressure from the expandable balloon 660.
  • a tip 655 is coupled to the distal end of the expandable balloon 660.
  • narrowing means e.g. O-rings or narrowing of the lumen
  • narrowing means e.g. O-rings or narrowing of the lumen
  • a hydrophilic coating may partially or fully coat the outer surface of the device, including the wire coil that is extended out. This will facilitate catheter tracking process and improve its pushability. Examples of suitable hydrophilic materials are provided hereinbefore.
  • the balloon may be provided in a folded configuration and covered by the deployment sheath. When in use, and at the site of action, the outer deployment sheath is retracted to a length which is at least equivalent to the total length of the balloon and the tip to allow the balloon to be deployed.
  • the device of the current design as described herein when used, it is consumed, in that the drug coating is left in the lumen of a patient.
  • the device may be suitable for the use of a therapeutic agent as defined hereinbefore in the preparation of a drug delivery device according to the concept of Initial Design, for example with reference, but not limited, to the particular embodiments discussed herein.
  • a possible method of treatment or surgery of a subject using balloon according to the current design may comprise the steps of:
  • an uncoated balloon catheter is introduced for pre-dilation to ensure a clear pathway for delivery of a drug coated balloon catheter;
  • the distal region of the drug coated balloon delivery system is positioned at a lesion and the outer sheath may be retracted in a proximal direction to expose the DEB or the distal region of the drug coated balloon delivery system is positioned before the lesion and the balloon catheter is advanced and positioned at the lesion and the DEB is exposed;
  • the balloon is inflated to a predetermined size to radially compress against an atherosclerotic plaque in the lesion to remodel the vessel wall;
  • the drug coated balloon delivery system may be retracted directly.
  • the outer sheath may be pushed forward or the balloon catheter is retracted into the outer sheath before the drug coated balloon delivery system is retracted.
  • the above method may be applicable to the treatment of any disease or condition that causes a narrowing or obstruction in a lumen of the body, such as, but not limited to, blood vessels (e.g. arteries, capillaries and veins).
  • blood vessels e.g. arteries, capillaries and veins.
  • This also includes non-vascular applications, such as benign prostatic hyperplasia (BPH), urethral strictures, ureteral strictures, prostate cancer, esophageal strictures, sinus strictures, biliary tract strictures, asthma and chronic obstructive pulmonary disease (COPD).
  • BPH benign prostatic hyperplasia
  • urethral strictures urethral strictures
  • ureteral strictures ureteral strictures
  • prostate cancer e.ophageal strictures
  • sinus strictures e.g. biliary tract strictures
  • asthma chronic obstructive pulmonary disease
  • the therapeutic agent coating layer on the surface of the film is protected by the outer sheath as the drug delivery system passes through the torturous blood vessel before it reaches the lesion.
  • the therapeutic agent coating in the drug delivery system can transit through blood vessels with different diameters, different tortuosity and through different distances without any drug loss until it reaches the lesion.
  • the drug loss in this process is well-controlled. This control can be further improved by reducing the friction between the therapeutic agent coating layer and the inner surface of outer sheath.
  • a lubricious inner lining can be added to the outer sheath, to minimise drug loss on transit of the balloon out of the outer sheath.
  • Drug transmission uniformity is well- controlled due to a uniform delivery of drug coating to the lesion, which also significantly enhances drug transfer and uptake.
  • an inflation tube 520 is located inside an outer sheath 510.
  • a rubber o-ring 530 bound to the inner lumen of the outer sheath, which in this example acts as the suction mechanism in combination with the inner lumen and the inflation tube/balloon.
  • Position A refers to the initial position.
  • Position B refers to the withdrawn position.
  • Component 530 may not be necessary in some cases, as long as there is a tight fit between outer sheath 510 and inner tube 520.
  • the suction mechanism described above is not applicable because it is not a closed system.
  • the closed portions of the outer sheath 680 may still contain air columns and therefore a system is needed to prevent such air bubbles from exiting the outer sheath and entering the bloodstream without flushing the gap between the inflation lumen 650 and the outer sheath.
  • the inner lumen of the outer sheath can contain one or more areas that are narrower than the rest of the outer sheath's inner diameter to limit the movement of any air column in the other portions of the outer sheath towards the slot.
  • the outer sheath generally has an inner diameter value X and the narrower areas are narrower by a value Y, such that these narrower areas have a diameter X-Y.
  • Said narrower areas in the inner diameter of the outer sheath may have a diameter that is less than or equal to 0.010" larger than the outer diameter of the inflation lumen 650.
  • Conventional inflation lumens may have an outer diameter of from 0.03" to 0.05".
  • Any suitable means to introduce such narrower sections may be used.
  • o-rings, headings or neck-down portions may be used to reduce the inner diameter of the outer sheath.
  • any suitable combination of these examples may be used.
  • Fig. 15a depicts an o-ring system where o-rings 690 are fitted at three positions of the outer sheath 680. As shown an o-ring 690 is fitted adjacent to the outer sheath portion that covers the balloon and two further o-rings 690 are positioned adjacent to the proximal and distal ends of the slot 681. It will be appreciated that an integrated beading may achieve the same effect.
  • Fig. 15b depicts a neck-down system where neck-down portions 695 are fitted at three positions of the outer sheath 680. As shown a neck-down portion 695 is fitted adjacent to the outer sheath portion that covers the balloon and two further neck-down portions 695 are positioned adjacent to the proximal and distal ends of the slot 681.
  • the function of the o- rings 690 or neck-down portions 695 is to separate the gap between the outer sheath and the inflation tube into several small compartments, such that when the outer sheath is retracted, the air column is locked between the outer sheath and the inflation tube by the o- rings 690 or neck-down portions 695 and prevent air bubbles escaping through the slot.
  • the number of o-rings 690 or neck-down portions 695 can be varied from case to case. As will be appreciated, only two narrower areas in the outer sheath may be needed to prevent escape of an air column through the longitudinal opening (i.e. either side of the longitudinal opening).
  • narrowing areas may also be applied to the OTW systems described herein.
  • the narrowing sections may be positioned to prevent the exit of air bubbles by application of the principles discussed above.
  • Test articles were coated with the same drug coating formulation and coating method. Test Articles
  • Device A is a drug delivery device prepared similar to Fig 6b.
  • the outer sheath distal tip is flared as shown in Fig. 11 b.
  • Device B is a drug delivery device is a normal DEB. No outer sheath is presented.
  • Balloons were inflated to pressure of 12 atm.
  • the catheter was delivered to the lesion site. The system was then flushed with an appropriate amount of water. The water was collected and the drug concentration was evaluated. The transition loss or navigation loss is equivalent to the total drug content inside the collected water divided by the total drug dose.
  • the transition loss of device A is ⁇ 5%, while the transition loss of device B is 30-50%.
  • the transition loss of device B is significantly higher than device A.
  • the wide range of transition loss of device B shows that the transition loss is uncontrollable and unpredictable as compared to that of device A.
  • Test articles were coated with the same drug coating formulation and coating method. Test Articles
  • Device C is a drug delivery device prepared similar to Fig 6b.
  • the outer sheath distal tip is straight as shown in Fig. 11a.
  • Device D is a drug delivery device prepared similar to Fig 6b.
  • the outer sheath distal tip is flared as shown in Fig. 11 b.
  • Balloons were inflated to pressure of 12atm.
  • the outer sheath was retracted at a curved channel. The system was then flushed with an appropriate amount of water. The water was collected and the drug concentration was evaluated. The unsheathing loss of the drug coating is equivalent to the total drug content inside the water divided by the total drug dose.
  • the unsheathing loss of device C is 5-10% and the unsheathing loss of device D is less than 2%. This indicates that the normal tip edge will press against and scratch-off the drug coating in a torturous path, while the flared tip can avoid tip edge contact with the coating. Therefore, the unsheathing loss will be minimized by using a flared tip design.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)
PCT/SG2018/050328 2017-07-05 2018-07-04 BALLOON CATHETER OF DRUG DELIVERY WO2019009809A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201880044739.9A CN111491687B (zh) 2017-07-05 2018-07-04 药物递送球囊导管

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762528661P 2017-07-05 2017-07-05
US62/528,661 2017-07-05

Publications (1)

Publication Number Publication Date
WO2019009809A1 true WO2019009809A1 (en) 2019-01-10

Family

ID=64951209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2018/050328 WO2019009809A1 (en) 2017-07-05 2018-07-04 BALLOON CATHETER OF DRUG DELIVERY

Country Status (2)

Country Link
CN (1) CN111491687B (zh)
WO (1) WO2019009809A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110559022A (zh) * 2019-04-30 2019-12-13 上海科赐医疗技术有限公司 具有操控器的医用非对称球囊导管
WO2020200184A1 (en) * 2019-04-01 2020-10-08 Vascuros Medical (Shanghai) Co., Ltd A method for removing free floating non-therapeutic drug particles released from a drug coated balloon catheter
GB2622233A (en) * 2022-09-07 2024-03-13 Cook Medical Technologies Llc Medical balloon assembly, use thereof, and method of deploying a medical balloon assembly

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113018649B (zh) * 2021-02-05 2022-07-15 北京先瑞达医疗科技有限公司 一种药物输送导管及其制备方法
CN113440180A (zh) * 2021-08-09 2021-09-28 首都医科大学附属北京友谊医院 一种基于ptc途径的胆道细胞刷及其使用方法
CN116549066B (zh) * 2023-07-05 2023-09-26 北京久事神康医疗科技有限公司 一种给药切割球囊导管

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009005933A1 (en) * 2007-06-29 2009-01-08 Xtent, Inc. Adjustable-length drug delivery balloon
US20090076448A1 (en) * 2007-09-17 2009-03-19 Consigny Paul M Methods and devices for eluting agents to a vessel
US20120136367A1 (en) * 2010-11-29 2012-05-31 Abbott Cardiovascular Systems, Inc. Multi-segment protective sheath for expandable medical devices
US20130090624A1 (en) * 2011-10-11 2013-04-11 Boston Scientific Scimed, Inc. Recapture sheath
US20130237950A1 (en) * 2010-09-17 2013-09-12 Abbott Cardiovascular Systems Inc. Length and diameter adjustable balloon catheter
US20140052104A1 (en) * 2011-07-25 2014-02-20 Terumo Kabushiki Kaisha Treatment device
US20140066897A1 (en) * 2012-09-05 2014-03-06 W. L. Gore & Associates, Inc. Retractable sheath devices, systems, and methods
US20160354585A1 (en) * 2013-07-15 2016-12-08 John P. Pigott Balloon catheter having a retractable sheath and locking mechanism with balloon recapture element
EP3103501A1 (en) * 2015-06-12 2016-12-14 Arravasc Limited A drug coated angioplasty balloon
WO2018093329A1 (en) * 2016-11-17 2018-05-24 Vascuros Medical Pte Ltd Drug eluting balloon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997562A (en) * 1997-06-13 1999-12-07 Percusurge, Inc. Medical wire introducer and balloon protective sheath
US10434292B2 (en) * 2011-06-24 2019-10-08 Access Closure Method and devices for flow occlusion during device exchanges

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009005933A1 (en) * 2007-06-29 2009-01-08 Xtent, Inc. Adjustable-length drug delivery balloon
US20090076448A1 (en) * 2007-09-17 2009-03-19 Consigny Paul M Methods and devices for eluting agents to a vessel
US20130237950A1 (en) * 2010-09-17 2013-09-12 Abbott Cardiovascular Systems Inc. Length and diameter adjustable balloon catheter
US20120136367A1 (en) * 2010-11-29 2012-05-31 Abbott Cardiovascular Systems, Inc. Multi-segment protective sheath for expandable medical devices
US20140052104A1 (en) * 2011-07-25 2014-02-20 Terumo Kabushiki Kaisha Treatment device
US20130090624A1 (en) * 2011-10-11 2013-04-11 Boston Scientific Scimed, Inc. Recapture sheath
US20140066897A1 (en) * 2012-09-05 2014-03-06 W. L. Gore & Associates, Inc. Retractable sheath devices, systems, and methods
US20160354585A1 (en) * 2013-07-15 2016-12-08 John P. Pigott Balloon catheter having a retractable sheath and locking mechanism with balloon recapture element
EP3103501A1 (en) * 2015-06-12 2016-12-14 Arravasc Limited A drug coated angioplasty balloon
WO2018093329A1 (en) * 2016-11-17 2018-05-24 Vascuros Medical Pte Ltd Drug eluting balloon

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020200184A1 (en) * 2019-04-01 2020-10-08 Vascuros Medical (Shanghai) Co., Ltd A method for removing free floating non-therapeutic drug particles released from a drug coated balloon catheter
CN110559022A (zh) * 2019-04-30 2019-12-13 上海科赐医疗技术有限公司 具有操控器的医用非对称球囊导管
CN110559022B (zh) * 2019-04-30 2023-11-24 上海科赐医疗技术有限公司 具有操控器的医用非对称球囊导管
GB2622233A (en) * 2022-09-07 2024-03-13 Cook Medical Technologies Llc Medical balloon assembly, use thereof, and method of deploying a medical balloon assembly

Also Published As

Publication number Publication date
CN111491687A (zh) 2020-08-04
CN111491687B (zh) 2023-03-24

Similar Documents

Publication Publication Date Title
WO2019009809A1 (en) BALLOON CATHETER OF DRUG DELIVERY
US8267886B2 (en) Catheter having a core wire and a low profile bond
EP2195068B1 (en) Balloon catheter for delivering a therapeutic agent
CN114010915B (zh) 一种药物洗脱球囊
US9867967B2 (en) Length and diameter adjustable balloon catheter
US5429605A (en) Microballoon catheter
US9327101B2 (en) Length and diameter adjustable balloon catheter
US8206370B2 (en) Dual lumen guidewire support catheter
CA2569792C (en) Catheter assembly
US6592569B2 (en) Protective sheath for catheters
JP5061614B2 (ja) カテーテル
US20140276585A1 (en) Length adjustable balloon catheter for multiple indications
US20060036309A1 (en) Guidewire loaded stent for delivery through a catheter
US9623216B2 (en) Length and diameter adjustable balloon catheter for drug delivery
US20160271363A1 (en) Stiffness adjustable catheter
US20110137245A1 (en) Balloon catheter with embedded rod
US20170007810A1 (en) Methods and devices for maintaining an open pathway in a vessel
WO2015077545A1 (en) Drug delivery system
JP4833039B2 (ja) カテーテル
WO2023195024A1 (en) Dual purpose catheter for wire trap and guide extension
JP2004357872A (ja) 体腔内拡張用カテーテル

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18828096

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18828096

Country of ref document: EP

Kind code of ref document: A1